ClinicalTrials.gg
RecruitingNCT07363044OMICROHNUpdated Nov 3, 2026

A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease

An interventional study of Epigenome-Guided Treatment Arm and Investigator-Guided Treatment Arm in Crohn Disease (CD), sponsored by Alimentiv Inc.. Recruiting at 51 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Alimentiv Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Feb 2025, registered Jan 2026).
  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Nov 3, 2026First site in HungarySite recruiting status changed+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 194 studies in Crohn Disease with a site in Belgium — 41 open to participants now, 56 under way, 29 of them phase 3. Crohn Disease · Belgium.

Planned enrollment
60th of 175
378 · median 211
Started
2025
with 12 others
No phase
12 of 194
8 open now
Primary completion
2028-08
later than 34 of 55 live
Registered
189th of 194
by date

Among the 194 studies in Crohn Disease with a site in Belgium, this one is the 60th largest by planned enrollment of the 175 interventional ones that give a count, is one of 13 that started in 2025, is one of 12 with no phase, reaches primary completion later than 34 of the 55 other live ones, and was the 189th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

41 of the 194 studies in Crohn Disease with a site in Belgium are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Crohn Disease with a site in Belgium, or all of them as a file.
02

Study summary

This is a multicentre, prospective, randomised, controlled, open-label study to assess the efficacy, safety, and cost-effectiveness of epigenome-guided treatment selection compared to usual standard-of-care (SOC) treatment selection in patients initiating biologic therapy for the treatment of their active Crohn's Disease (CD).

Read the detailed description

This trial will include 378 participants with active CD, defined as an HBI > 4 and the presence of endoscopic ulceration. Approximately 50% of the enrolled population will be bio-naïve and 50% exposed to no more than 1 prior biologic.

Eligible participants will be randomised 1:1 to either epigenome-guided treatment selection or usual SOC treatment selection. Randomization will be stratified by prior biologic use (yes/no) and corticosteroid use (yes/no) at baseline.

Blood samples for the assessment will be collected for all participants during screening. Peripheral blood will be tested via a machine-learning-powered epigenetic biomarker assay. EpiPredict is a software designed for CSV file input, data transfer, storage, and display, and will be serving as a EpiPredict clinical decision support system. It recommends treatment selections for 2 biologics (Vedolizumab (VDZ) and Vedolizumab (UST)) for CD utilizing genetic data.

The intervention (EpiPredict software) will indicate the probability of response to both VDZ and UST (though sites will only be provided with the treatment with the highest outcome) for the treatment of CD using a hybrid capture-based methylation assay (approved for research use only) and the EpiPredict software.

All participants in the study will be administered their biologic therapy in accordance with the product label and local SOC recommendations. Dose adjustments will be allowed in both groups at the treating investigator's discretion.

During the 26-week treatment period, the study assessments will follow the SOC regimen of the assigned biologic treatment. For participants receiving VDZ, study assessments are to occur at Weeks 6, 14, and 26; for participants receiving UST, study assessments are to occur at Weeks 8, 16, and 26.

Long-term follow up assessments are to occur every 6 months (Months 12, 18, and 24) after Week 26. Data for long-term follow up assessments will be collected from the participant's medical records captured at routine SOC visits and online questionnaires.

03

Conditions studied

  • Crohn Disease (CD)

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria for enrolment into the study:

  1. Aged 18 years or older at the time of .
  2. Documented diagnosis of ileal, ileocolonic, or colonic CD (may be confirmed at baseline study endoscopy).
  3. Active CD, as defined by HBI > 4 and SES-CD ≥ 6 for colitis/ileocolitis and ≥ 4 for ileitis only.
  4. Eligible to receive either VDZ and/or UST therapy for the treatment of CD per the approved drug label requirements and in the opinion of the treating physician.
  5. Must meet all eligibility criteria for biologic therapy initiation as per local SOC, including absence of chronic/opportunistic infections as demonstrated by local protocols for , tuberculosis, active cytomegalovirus, and C, and Clostridioides difficile infection. Local vaccination protocols apply as per SOC.
  6. Nonpregnant and nonlactating. Participants of must agree to follow local SOC guidelines for use of biologics in pregnancy/lactation, including appropriate , during the study; must agree to avoid becoming pregnant from the time of informed consent up until Week 26.
  7. If receiving nonbiologic therapies for inflammatory bowel disease, including thiopurines and methotrexate, must have initiated at least 3 months prior to screening and must be on a stable dose for at least 2 weeks prior to screening.
  8. If receiving oral , the participant is eligible if they meet all the following criteria:

    • The dose is up to a maximum of prednisone ≤ 40 mg/day or budesonide ≤ 9 mg/day or equivalent.
    • The dose has been stable for ≥ 2 weeks prior to screening.
    • The participant is willing to initiate a corticosteroid taper within 2 weeks after initiating biologic treatment.
  9. In the opinion of the investigator, the participant is able to understand and comply with protocol requirements including treatment as assigned per the protocol.
  10. Able to participate fully in all aspects of this clinical study. Full comprehension of consent language and informed consent must be obtained from the participant, or the participant's legally acceptable representative, and documented

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria are to be excluded from the study:

  1. Prior treatment with VDZ or UST.
  2. Prior treatment with more than 1 advanced therapy (eg, any biologic [ie, anti- tumour necrosis factor (TNF), anti-interleukin, anti-integrin]) or advanced oral small molecule [ie, Janus kinase inhibitor]) for CD.
  3. CD-related complications that in the opinion of the investigator would interfere with participation in the study, including but not limited to:

    • Ileorectal anastomosis (rectum \< 15 cm), or a proctocolectomy.
    • Short bowel syndrome.
    • All ostomies.
    • Symptomatic strictures in the bowel or symptomatic strictures in the ileum or ileocecal valve that have a stenosis.
    • Suspected or diagnosed active intra-abdominal or perianal abscess that have not been appropriately treated.
  4. History or current diagnosis of ulcerative colitis (unless this diagnosis was made erroneously), indeterminate colitis, idiopathic colitis (ie, colitis not consistent with CD), microscopic colitis, or colonic mucosal dysplasia (excluding dysplasia in resected adenomas).
  5. Increased risk of infectious complications (eg, recent pyogenic infection, any congenital or acquired immunodeficiency, or past organ, bone marrow, or stem cell transplantation).
  6. Any topical rectal therapy for treatment of CD within 2 weeks prior to the screening endoscopy.
  7. Nonsteroidal anti-inflammatory drugs (NSAIDs) as chronic treatment, except for cyclooxygenase-2logic selective NSAIDS (celecoxib).
  8. Faecal microbiota transplant (includes human microbiota-based therapeutics) within 4 weeks prior to randomisation.
  9. Any major surgery (in the investigator's opinion) performed within 8 weeks prior to randomisation or planned during the study.
  10. History of excessive alcohol or drug abuse that, in the opinion of the investigator, may interfere with the participant's ability to comply with the study procedures.
  11. Serious underlying disease other than CD that in the opinion of the investigator may interfere with the participant's ability to participate fully in the study or would compromise participant safety (such as history of , major neurological disorders, any unstable or uncontrolled medical disorder, or any known or suspected to any of the study biologics according to local prescribing information).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
378 participants (estimated)

Study arms

  • Other
    Investigator-Guided Treatment Arm

    Other: Investigator-Guided Treatment Arm

  • Experimental
    Epigenome-Guided Treatment Arm

    Device: Epigenome-Guided Treatment Arm

Interventions

  • DeviceEpigenome-Guided Treatment Arm

    Participants will receive UST or VDZ biologic therapy as indicated by an epigenome read-out of peripheral blood using a hybrid capture-based methylation assay. The assay and EpiPredict software will indicate the probability of response to VDZ and UST. The biologic with the predicted highest likelihood of success will be communicated to the investigator and the biologic initiated using standard dosing regimens.

  • OtherInvestigator-Guided Treatment Arm

    Assigned to UST or VDZ per conventional SOC and without the use or knowledge of epigenome results.

06

What researchers measure

Primary outcomes

  1. To compare the efficacy of epigenome-guided treatment selection to usual SOC treatment selection for inducing clinical remission and endoscopic response at Week 26 in participants with active CD.

    Corticosteroid-free clinical remission (Harvey-Bradshaw Index \[HBI\] score ≤ 4) and endoscopic response (≥ 50% decrease from baseline in the Simple Endoscopic Score for Crohn's Disease \[SES-CD\])

    Time frame: Baseline to Week 26

Secondary outcomes

  1. To explore the optimal threshold of EpiPredict results in predicting treatment response using data from participants assigned to the epigenome-guided treatment selection group

    Receiver-operating characteristic curve area analysis will be used Predicted likelihood of success of reaching corticosteroid-free clinical remission and endoscopic response

    Time frame: Baseline to Week 26

  2. To compare the efficacy of epigenome-guided treatment selection to usual SOC treatment selection for improving clinical and endoscopic outcome measures at Week 26 in participants with active CD

    Endoscopic response (≥ 50% decrease from baseline in SES-CD score) Endoscopic remission (SES-CD ≤ 3) Clinical remission (HBI ≤ 4) Corticosteroid-free clinical remission Clinical response (HBI ≤ 4 or decrease in HBI ≥ 3 points from baseline) Corticosteroid-free deep remission (HBI ≤ 4 and SES-CD ≤ 3)

    Time frame: Baseline to Week 26

  3. To evaluate the cost-effectiveness of epigenome-guided treatment selection compared to usual SOC treatment selection

    Societal costs as measured by the modified iMTA Medical Cost Questionnaire and modified iMTA Productivity Cost Questionnaire questionnaires Quality of life-years as measured by the European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) questionnaire

    Time frame: Baseline to 24 Months

Other outcomes

  1. To assess the safety of a treatment based on epigenome-guided treatment selection compared to usual SOC treatment selection

    Adverse events CD-related complications, hospitalisations, and/or surgeries

    Time frame: Baseline to Week 26

  2. To explore additional efficacy measures of epigenome-guided treatment selection compared to usual SOC treatment selection at Week 26 in participants with active CD.

    Achieving a minimally clinically important difference in patient-reported health-related quality of life (HRQOL) compared to baseline as measured by the EQ-5D-5L Clinical remission (HBI ≤ 4) Clinical response (HBI ≤ 4 or decrease in HBI ≥ 3 points from baseline) Clinical remission (Crohn's Disease Activity Index \[CDAI\] score of \< 150) over time Time to clinical remission (HBI ≤ 4) No drainage on gentle finger compression in participants with draining fistulas Extra-intestinal manifestations Histologic response, as defined in the statistical analysis plan (SAP) Histologic remission, as defined in the SAP Whether the participant achieved 25%, 50%, and 75% reduction from baseline in the Robarts Histopathology Index (RHI) score Serum trough concentrations of biologic drug Biochemical remission CRP ≤ 5.0 mg/L and/or fecal calprotectin \[FC\] \< 250 µg/g) Change in the Symptoms and Impact Questionnaire-CD (SIQ-CD) score

    Time frame: Baseline to Week 26

  3. In a subset (~30%) of participants, to evaluate response by intestinal ultrasound (IUS) in participants assigned to epigenome-guided treatment selection compared to usual SOC treatment selection

    Proportion of participants with IUS response (defined as by reduction in bowel wall thickness \[BWT \> 25%\] or \[\> 2.0 mm\] or \[\> 1.0 mm and one colour Doppler signal (CDS) reduction\]) Proportion of participants with transmural remission (defined by BWT ≤ 3 mm and normal/0 CDS) Proportion of participants with transmural remission and endoscopic remission

    Time frame: Baseline to Week 26

07

Study locations

40 of 51 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Aug 2028, 42 months after the start.

Of 290 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 42 months is close to that.

Counting every sponsor, half of 302 studies reached it within 45 months; a quarter within 21 and three quarters within 65.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Jun 2027 → Aug 2028 and completion Jan 2029 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Jan 23, 2026
StartActual
Feb 1, 2025
Primary completionEst.
Aug 2028was Jun 2027
CompletionEst.
Dec 2028was Jan 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
14 sites added, 2 sites removed — first site in Hungary. 4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • IRCCS "Saverio de Bellis", National Institute of Gastroenterology · Castellana Grotte, ItalyNot yet recruiting→Recruiting
  • Agostino Gemelli University Policlinic · Roma, ItalyNot yet recruiting→Recruiting
  • UOC di Gastroenterologia ed Endoscopia Digestiva · San Giovanni Rotondo, ItalyNot yet recruiting→Recruiting
  • UKC Ljubljana · Ljubljana, SloveniaNot yet recruiting→Recruiting
Show 14 added (5 Hungary, 3 Belgium, 3 Italy, 2 Netherlands, 1 United Kingdom)
  • ZAS Middelheim · Antwerp, Belgium
  • ZAS Vincentius · Antwerp, Belgium
  • AZ Sint Jan · Bruges, Belgium
  • Eszak-Pesti Centrumkorhaz-Honvedkorhaz · Budapest, Hungary
  • Semmelweis Egyetem Sebészeti · Budapest, Hungary
  • Debreceni Egyetem Klinikai Kozpont · Debrecen, Hungary
  • Pecsi Tudomanyegyetem Klinikai Kozpont · Pécs, Hungary
  • Szegedi Tudományegyetem, Szent-Györgyi Albert Klinikai Központ · Szeged, Hungary
  • S. Maria del Prato Hospital · Feltre, Italy
  • IRCCS Sacro Cuore Don Calabria · Negrar, Italy
  • Azienda Ospedale Università Padova · Padova, Italy
  • Catharina Ziekenhuis · Eindhoven, Netherlands
  • St. Antonius Ziekenhuis · Nieuwegein, Netherlands
  • Barts Health NHS Trust · London, United Kingdom
Show 2 removed
  • GZA Antwerpen · Antwerp, Belgium
  • UZ Leuven Gasthuisberg · Leuven, Belgium
Nov 3, 2026
Primary completion
Jun 2027→Aug 2028
Nov 3, 2026
Study completion
Jan 2029→Dec 2028
Nov 3, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedActive CD, as defined by HBI > 64 and SES-CD ≥ 6 for colitis/ileocolitis and ≥ 4 for ileitis only.
Nov 3, 2026
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionTo compare the efficacy of epigenome-guided treatment selection to usual SOC treatment selection for improving clinical and endoscopic outcome measures at Week 26 in participants with active CD: how it is measured was reworded
  • Descriptionother outcomeTo explore additional efficacy measures of epigenome-guided treatment selection compared to usual SOC treatment selection at Week 26 in participants with active CD.: how it is measured was reworded
Nov 3, 2026
Contact
Study contact changed: s•••@alimentiv.com→j•••@alimentiv.com. See the current contact
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    14 sites added, 2 sites removed — first site in Hungary. 4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • IRCCS "Saverio de Bellis", National Institute of Gastroenterology · Castellana Grotte, ItalyNot yet recruiting→Recruiting
    • Agostino Gemelli University Policlinic · Roma, ItalyNot yet recruiting→Recruiting
    • UOC di Gastroenterologia ed Endoscopia Digestiva · San Giovanni Rotondo, ItalyNot yet recruiting→Recruiting
    • UKC Ljubljana · Ljubljana, SloveniaNot yet recruiting→Recruiting
    Show 14 added (5 Hungary, 3 Belgium, 3 Italy, 2 Netherlands, 1 United Kingdom)
    • ZAS Middelheim · Antwerp, Belgium
    • ZAS Vincentius · Antwerp, Belgium
    • AZ Sint Jan · Bruges, Belgium
    • Eszak-Pesti Centrumkorhaz-Honvedkorhaz · Budapest, Hungary
    • Semmelweis Egyetem Sebészeti · Budapest, Hungary
    • Debreceni Egyetem Klinikai Kozpont · Debrecen, Hungary
    • Pecsi Tudomanyegyetem Klinikai Kozpont · Pécs, Hungary
    • Szegedi Tudományegyetem, Szent-Györgyi Albert Klinikai Központ · Szeged, Hungary
    • S. Maria del Prato Hospital · Feltre, Italy
    • IRCCS Sacro Cuore Don Calabria · Negrar, Italy
    • Azienda Ospedale Università Padova · Padova, Italy
    • Catharina Ziekenhuis · Eindhoven, Netherlands
    • St. Antonius Ziekenhuis · Nieuwegein, Netherlands
    • Barts Health NHS Trust · London, United Kingdom
    Show 2 removed
    • GZA Antwerpen · Antwerp, Belgium
    • UZ Leuven Gasthuisberg · Leuven, Belgium
    Primary completion Jun 2027→Aug 2028
    Study completion Jan 2029→Dec 2028
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedActive CD, as defined by HBI > 64 and SES-CD ≥ 6 for colitis/ileocolitis and ≥ 4 for ileitis only.
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionTo compare the efficacy of epigenome-guided treatment selection to usual SOC treatment selection for improving clinical and endoscopic outcome measures at Week 26 in participants with active CD: how it is measured was reworded
    • Descriptionother outcomeTo explore additional efficacy measures of epigenome-guided treatment selection compared to usual SOC treatment selection at Week 26 in participants with active CD.: how it is measured was reworded
    Contact Study contact changed: s•••@alimentiv.com→j•••@alimentiv.com. See the current contact
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07363044
Lead sponsor
Alimentiv Inc.
Collaborators
The Leona M. and Harry B. Helmsley Charitable Trust, Horizon Europe, Stichting Amsterdam UMC
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Feb 1, 2025
Primary completion
Aug 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Jennifer Earle
Contact
jennifer.earle@alimentiv.com
Lauren Schleicher
Contact
lauren.schleicher@alimentiv.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion